Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.17 | — | — | — | — | — | — | — | — | — | — | 4.42 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 50.75 | 102.26 | 46.67 | 9.19 | 6.96 | 84.97 | 91.27 | 34.39 | 16.44 | 15.01 | 20.09 | 35.53 | 34.77 |
| — | +20.4% | -48.9% | -73.3% | -57.7% | +466.0% | +354.2% | -3.2% | -52.7% | -95.4% | -81.3% | -60.7% | +149.5% | |
| P/B Ratio | — | — | 88.08 | 7.69 | — | 4.02 | 1.67 | 1.43 | 1.01 | 0.69 | 0.77 | 1.11 | 0.96 |
| — | — | +5166.8% | +437.7% | — | +486.9% | +117.2% | +28.6% | +4.8% | -39.1% | -33.3% | -53.9% | -68.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 1.33 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | 1.41 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Insight Molecular Diagnostics Inc.'s operating margin was -4249.2% in Q3 2025, down 2349.2 pp QoQ and up 7502.9 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -2182.5% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 23.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.3% | 53.5% | 67.6% | 62.0% | 40.0% | 43.5% | 48.1% | 25.6% | -30.3% | 57.8% | 58.7% | 3.4% | -1.5% |
| — | +23.0% | +40.5% | +142.4% | +232.3% | -24.8% | -18.2% | +659.4% | -1972.4% | +114.4% | +349.1% | -94.8% | -103.8% | |
| Operating Margin | -3245.1% | -4249.2% | -1900.0% | -318.0% | -2262.9% | -11752.2% | -4453.8% | -5265.3% | -5152.5% | -1518.2% | -1791.4% | 1969.7% | -4251.1% |
| — | +63.8% | +57.3% | +94.0% | +56.1% | -674.1% | -148.6% | -367.3% | -21.2% | +40.4% | -161.1% | +348.1% | -327.6% | |
| Net Margin | -3225.0% | -4174.6% | -1880.7% | -312.0% | -2255.1% | -11733.0% | -4355.8% | -5186.9% | -5093.0% | -1512.6% | -1799.8% | 1021.2% | -16415.3% |
| — | +64.4% | +56.8% | +94.0% | +55.7% | -675.7% | -142.0% | -607.9% | +69.0% | +89.1% | +48.6% | +137.7% | -1541.8% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1480.7% | — | -172.2% | -65.3% | — | -83.3% | -22.9% | -48.8% | -55.1% | -15.1% | -19.3% | 7.8% | -77.2% |
| — | — | -653.0% | -33.7% | — | -451.0% | -18.3% | -724.1% | +28.7% | -33.5% | -68.8% | +146.4% | -77.1% | |
| ROA | -110.3% | -23.0% | -17.6% | -14.0% | -63.7% | -18.6% | -6.2% | -12.5% | -20.4% | -7.7% | -9.8% | 3.3% | -34.9% |
| — | -23.4% | -182.6% | -11.7% | -211.4% | -142.6% | +36.4% | -477.4% | +41.5% | -35.0% | -87.0% | +149.3% | -59.6% | |
| ROIC | — | — | — | — | — | -73.8% | -21.9% | -48.6% | -59.5% | -16.0% | -19.6% | 16.7% | -24.4% |
| — | — | — | — | — | -360.7% | -11.6% | -391.5% | -144.4% | -503.7% | -625.1% | +396.6% | +54.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 429.6% YoY to 2.79x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 3.07 | 0.34 | — | 0.41 | 0.16 | 0.20 | 0.14 | 0.08 | 0.06 | 0.09 | 0.09 |
| — | — | +1802.5% | +72.7% | — | +402.2% | +149.0% | +124.9% | +56.6% | +67.2% | +25.7% | -16.4% | +2.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 0.53 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.62 | 2.79 | 4.04 | 3.75 | 1.62 | 0.53 | 1.38 | 0.78 | 1.49 | 2.11 | 2.74 | 1.66 | 2.11 |
| — | +429.6% | +191.4% | +377.2% | +8.7% | -75.0% | -49.4% | -52.7% | -29.5% | -25.5% | -21.5% | -6.0% | -23.9% | |
| Quick Ratio | 1.56 | 2.73 | 3.93 | 3.70 | 1.56 | 0.50 | 1.38 | 0.78 | 1.49 | 2.11 | 2.74 | 1.66 | 2.11 |
| — | +444.2% | +183.9% | +371.2% | +4.9% | -76.2% | -49.4% | -52.7% | -29.5% | -25.5% | -21.5% | -6.0% | -23.3% | |
| Interest Coverage | -726.68 | -380.97 | -393.68 | -234.45 | -1120.90 | -435.97 | -579.00 | -617.80 | -101.12 | -465.21 | -592.43 | 531.82 | -970.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonInsight Molecular Diagnostics Inc.'s current P/E is -1.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Insight Molecular Diagnostics Inc.'s current operating margin is -3245.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Insight Molecular Diagnostics Inc.'s business trajectory between earnings reports.